GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Retrieved on: 2022-12-31 06:23:26

Tags for this article:

Click the tags to see associated articles and topics

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market. View article details on hiswai:

Excerpt

30, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on ...

Article found on: indiashorts.com